Fig. 5From: The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancerThe overall signalling pathway. ERα-induced effects of oestrogen promote the expression of NRF2 by the binding of ERα to the NRF2 promoter at the site between − 1434 and − 1417 bp. The ERα-NRF2 signalling axis enhances the sensitivity of prostate cancer cells to bicalutamide by promoting the expression of resistance-related genesBack to article page